Display options
Cite
Ota Y, Takahashi K, Otake S, et al. Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth. FEBS Open Bio. 2021;11(12):3276-3292doi: 10.1002/2211-5463.13294.
Ota, Y., Takahashi, K., Otake, S., Tamaki, Y., Okada, M., Yan, I., Aso, K., Fujii, S., Patel, T., & Haneda, M. (2021). Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth. FEBS open bio, 11(12), 3276-3292. https://doi.org/10.1002/2211-5463.13294
Ota, Yu, et al. "Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth." FEBS open bio vol. 11,12 (2021): 3276-3292. doi: https://doi.org/10.1002/2211-5463.13294
Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M. Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth. FEBS Open Bio. 2021 Dec;11(12):3276-3292. doi: 10.1002/2211-5463.13294. Epub 2021 Sep 22. PMID: 34510808; PMCID: PMC8634862.
Copy Download .nbib Format: NLM
Share it on

FEBS Open Bio. 2021 Dec;11(12):3276-3292. doi: 10.1002/2211-5463.13294. Epub 2021 Sep 22.

Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth.

FEBS open bio

Yu Ota, Kenji Takahashi, Shin Otake, Yosui Tamaki, Mitsuyoshi Okada, Irene Yan, Kazunobu Aso, Satoshi Fujii, Tushar Patel, Masakazu Haneda

Affiliations

  1. Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan.
  2. Departments of Transplantation and Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
  3. Department of Laboratory Medicine, Asahikawa Medical University, Japan.

PMID: 34510808 PMCID: PMC8634862 DOI: 10.1002/2211-5463.13294

Abstract

Extracellular vesicles (EV) within the cellular secretome are emerging as modulators of pathological processes involved in tumor growth through their ability to transfer donor-derived RNA into recipient cells. While the effects of tumor and stromal cell EVs within the tumor microenvironment have been studied, less is known about the contributions of normal, nontransformed cells. We examined the impact of EVs within the cellular secretome from nonmalignant cells on transformed cell growth and behavior in cholangiocarcinoma cells. These effects were enhanced in the presence of the pro-fibrogenic mediator TGF-β. We identified miR-195 as a TGF-β responsive miRNA in normal cells that can be transferred via EV to tumor cells and regulate cell growth, invasion, and migration. The effects of miR-195 involve modulation of the epithelial-mesenchymal transition through direct effects on the transcription factor Snail. These studies provide in vitro and in vivo evidence for the impact of normal cellular secretome on transformed cell growth, show the importance of EV RNA transfer, and identify mechanisms of EV-mediated transfer of miRNA as a contributor to tumor development, which may provide new therapeutic opportunities for targeting human cholangiocarcinoma.

© 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Keywords: epithelial-mesenchymal transition; extracellular vesicles; microRNA; secretome; tumor microenvironment

References

  1. Mol Cancer Res. 2014 Oct;12(10):1377-87 - PubMed
  2. J Hepatol. 2014 Jun;60(6):1268-89 - PubMed
  3. Peptides. 2018 Sep;107:54-60 - PubMed
  4. Cell Physiol Biochem. 2018;48(2):801-814 - PubMed
  5. J Biol Chem. 2012 Jan 6;287(2):1397-405 - PubMed
  6. Oncotarget. 2017 Sep 15;8(59):99757-99771 - PubMed
  7. Genes Cancer. 2018 Mar;9(3-4):87-100 - PubMed
  8. Cell. 2016 Mar 10;164(6):1226-1232 - PubMed
  9. PLoS One. 2009 Oct 26;4(10):e7542 - PubMed
  10. Mol Cancer Res. 2020 Oct;18(10):1574-1588 - PubMed
  11. Hepatology. 2009 Jul;50(1):113-21 - PubMed
  12. J Cell Biol. 2018 Jan 2;217(1):65-77 - PubMed
  13. Clinics (Sao Paulo). 2018 Jul 10;73:e184 - PubMed
  14. Cancer Cell. 2016 Dec 12;30(6):836-848 - PubMed
  15. Genes Dis. 2017 Dec 09;5(1):36-42 - PubMed
  16. Cancer Res. 2012 Oct 1;72(19):4883-9 - PubMed
  17. J Clin Invest. 2016 Apr 1;126(4):1163-72 - PubMed
  18. Physiol Genomics. 2011 May 13;43(9):479-87 - PubMed
  19. PLoS One. 2015 Dec 09;10(12):e0144073 - PubMed
  20. Aging (Albany NY). 2018 May 18;10(5):1000-1014 - PubMed
  21. J Extracell Vesicles. 2013 Jun 18;2: - PubMed
  22. Oncotarget. 2018 Mar 27;9(23):16400-16417 - PubMed
  23. PLoS One. 2013;8(3):e60155 - PubMed
  24. Hepatology. 2011 Oct;54(4):1237-48 - PubMed
  25. Hepatology. 2017 Feb;65(2):501-514 - PubMed
  26. Mol Genet Genomics. 2018 Oct;293(5):1245-1253 - PubMed
  27. Int J Biol Macromol. 2018 Dec;120(Pt A):975-984 - PubMed
  28. Ther Adv Med Oncol. 2020 Sep 16;12:1758835920953293 - PubMed
  29. J Cell Sci. 2014 Apr 1;127(Pt 7):1585-94 - PubMed
  30. J Gastroenterol. 2019 Sep;54(9):763-773 - PubMed
  31. Gastroenterol Jpn. 1987 Aug;22(4):474-9 - PubMed
  32. Arch Toxicol. 2016 Feb;90(2):403-14 - PubMed
  33. Cell Mol Life Sci. 2011 Aug;68(16):2667-88 - PubMed
  34. Oncol Lett. 2018 Apr;15(4):5947-5951 - PubMed

Publication Types

Grant support